Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14728214.2020.1810663 http://scihub22266oqcxt.onion/10.1080/14728214.2020.1810663 32799566!ä!32799566 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Emerg+Drugs 2020 ; 25 (3): 337-351 Nephropedia Template TP {{tp|p=32799566|t=2020. Emerging therapeutics for the management of COVID 19 |pdf=|usr=}}{{32799566}} gab.com Text Emerging therapeutics for the management of COVID 19 JO: Expert Opin Emerg Drugs http://www.kidney.de/pget.php?&tw=1&pmid=32799566 #FOAvip INTRODUCTION: The coronavirus-19 (COVID-19) disease pandemic can be characterized as the most critical and changeable hazard to healthcare systems in eras. The high fatality rate associated with coronavirus infection underlines the urgent need for an effective treatment to reduce disease severity and mortality. AREAS COVERED: A detailed search for treatments related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) was carried out using PubMed. Components of the virus relevant to the infectious mechanism were identified. We have highlighted all the latest emerging and repurposed drugs that were found to be active against this novel coronavirus and classified these drugs according to their category. Different drug targets are discussed in order to identify new molecules or new combinations as candidates to manage SARS-CoV2/COVID-19 infections. EXPERT OPINION: The development of novel molecules and vaccines has been a challenge during this urgent crisis. Nucleoside analogs and IL-6 receptor antagonists have been identified as the best candidates for treatment of this disease. Multi-drug therapy by targeting different pathways will need to be corroborated and then confirmed through clinical trials. Until a vaccine is available, an alternative drug regimen needs to be adopted by clinicians in the management of coronavirus symptoms. Twit Text FOAVip Emerging therapeutics for the management of COVID 19 ????Expert Opin Emerg Drugs http://www.kidney.de/pget.php?&tw=1&pmid=32799566 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32799566 #FOAvip English Wikipedia <ref>{{Cite pmid|32799566}}</ref> Emerging therapeutics for the management of COVID 19 #MMPMID32799566 Debnath SK; Srivastava R; Omri A Expert Opin Emerg Drugs 2020[Sep]; 25 (3): 337-351 PMID32799566show ga INTRODUCTION: The coronavirus-19 (COVID-19) disease pandemic can be characterized as the most critical and changeable hazard to healthcare systems in eras. The high fatality rate associated with coronavirus infection underlines the urgent need for an effective treatment to reduce disease severity and mortality. AREAS COVERED: A detailed search for treatments related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) was carried out using PubMed. Components of the virus relevant to the infectious mechanism were identified. We have highlighted all the latest emerging and repurposed drugs that were found to be active against this novel coronavirus and classified these drugs according to their category. Different drug targets are discussed in order to identify new molecules or new combinations as candidates to manage SARS-CoV2/COVID-19 infections. EXPERT OPINION: The development of novel molecules and vaccines has been a challenge during this urgent crisis. Nucleoside analogs and IL-6 receptor antagonists have been identified as the best candidates for treatment of this disease. Multi-drug therapy by targeting different pathways will need to be corroborated and then confirmed through clinical trials. Until a vaccine is available, an alternative drug regimen needs to be adopted by clinicians in the management of coronavirus symptoms. |*Disease Management[MESH] |*Drug Design[MESH] |Animals[MESH] |Anti-Inflammatory Agents/administration & dosage[MESH] |Anticoagulants/administration & dosage[MESH] |Antiviral Agents/*administration & dosage[MESH] |Betacoronavirus/*drug effects/physiology[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/diagnosis/*drug therapy/epidemiology/therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/epidemiology[MESH] |SARS-CoV-2[MESH] |Vasodilator Agents/administration & dosage[MESH]Emerging therapeutics for the management of COVID 19 (epmc).pdf DeepDyve Pubget Overpricing